A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
for Carcinoma, Transitional Cell
62 locations incl. Huntsville
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT07218380·Phase 3·Recruiting·Listed Oct 2025
UCSF Medical Center at Mission Bay
Clinical research site in San Francisco, California · 1600 DIVISADERO ST, ROOM 303A, SAN FRANCISCO, CA 94115-3010 · (415) 335-3776 · Website
Part of UCSF
As of July 2026, 13 paid clinical trials are recruiting at UCSF Medical Center at Mission Bay in San Francisco, California. Active studies at this site cover conditions such as Carcinoma, Transitional Cell, Urinary Bladder Neoplasms and Neoplasm Metastasis. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Recruiting clinical trials at UCSF Medical Center at Mission Bay (13)
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
for Breast Neoplasms
116 locations incl. Anchorage
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT07174336·Phase 3·Recruiting·Listed Sep 2025
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
for Carcinoma, Non-Small-Cell Lung
48 locations incl. Gilbert
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06623422·Phase 3·Recruiting·Listed Oct 2024
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
for Ovarian Cancer
32 locations incl. Birmingham
Sponsor: Merck Sharp & Dohme LLC
Sex: Female·Age: 18+
Code: NCT06824467·Phase 3·Recruiting·Listed Feb 2025
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
for Breast Cancer
24 locations incl. Los Angeles
Sponsor: Eli Lilly and Company
Sex: All·Age: 18+
Code: NCT05768139·Phase 1, Phase 2·Recruiting·Listed Mar 2023
A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
for Cytomegalovirus Prophylaxis
18 locations incl. Birmingham
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: Up to 17
Code: NCT07199465·Phase 1·Recruiting·Listed Sep 2025
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
for Ulcerative Colitis
11 locations incl. San Francisco
Sponsor: Eli Lilly and Company
Sex: All·Age: 2 - 19
Code: NCT04844606·Phase 3·Recruiting·Listed Apr 2021
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
for Locally Advanced or Metastatic ER+ HER2- Breast Cancer
21 locations incl. Los Angeles
Sponsor: Pfizer
Sex: All·Age: 18+
Code: NCT04606446·Phase 2·Recruiting·Listed Oct 2020
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
for Bladder Cancer
4 locations incl. San Francisco
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT07232602·Phase 1, Phase 2·Recruiting·Listed Nov 2025
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
for Malignant Melanoma
5 locations incl. Springdale
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06961006·Phase 2·Recruiting·Listed May 2025
Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03)
for Renal Cell Carcinoma
7 locations incl. San Francisco
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18 - 120
Code: NCT07049926·Phase 1, Phase 2·Recruiting·Listed Jul 2025
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
for Castration-Resistant Prostatic Cancer
9 locations incl. Los Angeles
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06863272·Phase 1, Phase 2·Recruiting·Listed Mar 2025
Full-Avoidance vs. Permissive/Regulated Drinking & Outcomes On Fibrillation
for Atrial Fibrillation (AF)
2 locations in San Francisco
Sponsor: University of California, San Francisco
Sex: All·Age: 21+
Code: NCT06754176·Recruiting·Listed Dec 2024
More research sites in San Francisco
- University of California, San Francisco (321 trials)
- University of California San Francisco (163 trials)
- Power Life Sciences (61 trials)
- UCSF Medical Center-Mission Bay (38 trials)
- UCSF (34 trials)
- Kaiser Permanente-San Francisco (34 trials)
- Zuckerberg San Francisco General Hospital (25 trials)
- UCSF Helen Diller Family Comprehensive Cancer Center (23 trials)
- UCSF Medical Center (22 trials)
- California Pacific Medical Center-Pacific Campus (21 trials)
Explore more
Paid clinical trials in San Francisco, CA · California clinical trials